For the first time in more than two decades, the U.S. sunscreen market is getting a major update. The U.S. Food and Drug Administration (FDA) has expanded its list of approved sunscreen active ingredients to include bemotrizinol (BEMT) — marking the first new organic UV filter approved in the United States since 1999.
Dermatologists and skin cancer experts are calling this a significant step forward for sun protection in the U.S., bringing American formulations closer to what has long been available in Europe and other regions.
What Is Bemotrizinol?
Bemotrizinol, also known as bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), is a broad-spectrum ultraviolet (UV) filter that has been used internationally since 2000.
According to the recent dermatology publication on its pending FDA approval, bemotrizinol:
- Provides strong protection against UVB (290–320 nm)
- Covers UVA2 (320–340 nm)
- Extends into UVA1 (340–400 nm)
- Addresses the long-recognized “320-nm gap” in current U.S. sunscreen protection
This “320-nm gap” refers to a region between UVB and UVA wavelengths that has not been adequately covered by currently approved U.S. sunscreen filters. By filling that gap, bemotrizinol offers more continuous and complete broad-spectrum protection.
Why This Approval Is a Big Deal
Until now, U.S. sunscreen formulators have relied on just seven commonly used UV filters:
- Zinc oxide
- Titanium dioxide
- Avobenzone
- Octocrylene
- Homosalate
- Octisalate
- Ensulizole
In contrast, the European Union has nearly 30 approved UV filters. The limited U.S. list has made it harder for manufacturers to create advanced formulations with optimal UVA protection and cosmetic appeal.
The FDA’s decision to expand sunscreen options represents the first approval of a new organic (chemical) UV filter since ensulizole in 1999 . That makes bemotrizinol the first addition in more than 20 years.
What Makes Bemotrizinol Different?
1. True Broad-Spectrum Coverage
Bemotrizinol absorbs across both UVB and UVA wavelengths, including long-wave UVA1 rays, which are linked to:
- Skin aging
- Pigment changes
- Skin cancer risk
This extended coverage strengthens the “broad-spectrum” claim in sunscreen labeling.
2. High Photostability
One challenge with current U.S. sunscreens is that avobenzone, the only FDA-approved long-wave UVA filter, is photounstable. It breaks down when exposed to sunlight and must be stabilized with other ingredients like octocrylene .
Bemotrizinol is highly photostable. That means:
- It does not degrade easily in sunlight
- It maintains protection longer
- It can improve the overall stability of sunscreen formulas
3. Minimal Skin Absorption
Safety has been a key focus in sunscreen regulation. According to clinical pharmacokinetic studies reviewed by the FDA, bemotrizinol has negligible systemic absorption. In maximal-use trials, plasma levels rarely exceeded 0.5 ng/L .
Its large molecular weight (over 500 Daltons) makes it unlikely to significantly penetrate intact skin — a principle sometimes referred to as the “500 Dalton rule” .
This contrasts with some smaller UV filters that have demonstrated measurable systemic absorption under heavy use conditions.
4. Better Formulation Flexibility
Unlike avobenzone, bemotrizinol can be combined with:
- Zinc oxide
- Titanium dioxide
- Other existing UV filters
This flexibility allows manufacturers to:
- Improve UVA protection
- Reduce total active ingredient concentrations
- Create more cosmetically elegant sunscreens
- Decrease visible whitening, especially important for darker skin tones
What the FDA Approval Means for Consumers
The FDA’s expansion of sunscreen options signals a modernization of U.S. sun protection standards. According to the agency’s recent announcement, bemotrizinol will be considered generally recognized as safe and effective (GRASE) for use at concentrations up to 6% in adults and children 6 months and older.
This approval could lead to:
- Stronger UVA protection in U.S. sunscreens
- More advanced and stable formulations
- Improved cosmetic feel and wearability
- Greater alignment with international sunscreen science
Over time, consumers may see products that offer higher UVA ratings with lighter textures and improved performance in heat and sunlight.
Why This Matters for Skin Cancer Prevention
Skin cancer remains the most common cancer in the United States. Broad-spectrum sunscreen that protects against both UVB and UVA radiation is a cornerstone of prevention.
By addressing gaps in UVA coverage and improving photostability, bemotrizinol may enhance real-world protection — especially during prolonged sun exposure.
This approval also highlights the importance of continued regulatory updates that balance:
- Scientific rigor
- Safety testing
- Innovation in sun protection
The Bottom Line
After more than 20 years without new sunscreen active ingredients, the FDA’s approval of bemotrizinol represents a major shift in U.S. sun care.
With strong broad-spectrum coverage, improved stability, minimal systemic absorption, and enhanced formulation flexibility, bemotrizinol could significantly upgrade the next generation of American sunscreens.
For consumers, that means better protection — and potentially a meaningful step forward in skin cancer prevention.
Sources
Wang SQ, Osterwalder U, Lim HW. Pending Food and Drug Administration approval of bemotrizinol: A potential turning point for United States sunscreen formulation. J Am Acad Dermatol. 2026. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0190962226025697
U.S. Food and Drug Administration. FDA expands sunscreen options for first time in 20 years. 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years
